effects of Uric-acid-lowering agent, FebuxOstat on subclinical inflammation in patients with hyperuricemia (UFO study)
Not Applicable
Recruiting
- Conditions
- hyperuricemia
- Registration Number
- JPRN-UMIN000009262
- Lead Sponsor
- FO study Investigators
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
(1) patients with history of gout (2) patients with malignancy, or other serious illness (3) patients with allergy to febuxostat (4) patients treated with mercaptopurine or azathioprine (5) patients not recognized as appropriate to participate (6) patients under insulin treatment (7) serum creatinine levels higher than 1.5 mg/dl (8) patients with inflammatory disease such as rheumatic diseases or inflammatory bowel diseases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method serum high sensitivity C-reactive protein (CRP)
- Secondary Outcome Measures
Name Time Method (1) Changes of HOMA-IR between two groups (2) Changes of IMT, PWV (3) Effects on factors of metabolic syndrome (abdominal, blood pressure, fat, blood glucose) (4) Change of serum uric acid levels and achiving less than 6.0mg/dl of uric acid levels, (5) Changes of eGFR (6) Changes of albuminuria/creatinine (7) Changes of serum and urine biomarkers